Laboratório de Enzomologia e Controle do Metabolismo, Departamento de Fármacos, Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, 21941-590, Brazil.
Mol Genet Metab. 2011 Aug;103(4):394-8. doi: 10.1016/j.ymgme.2011.04.003. Epub 2011 Apr 16.
Human breast cancer tissues, as well as normal tissues from the same patients, were treated with clotrimazole (CTZ) and have their capacities for glucose consumption and lactate production evaluated. This treatment strongly decreased the lactate production rate by tumor tissues (85% inhibition) without affecting the other measurements made, i.e. lactate production by control tissues or glucose consumption by both, control and tumor tissues. This result directly correlates with the inhibition promoted by CTZ on the activity of the major regulatory glycolytic enzyme 6-phosphofructo-1-kinase (PFK) that was observed in tumor tissues (84% inhibition) but not in control tissues. Fractionation of the tissues revealed that this inhibition does not occur in the soluble fraction of the enzyme, but is exclusive of a particulate fraction. It has been previously shown that the particulate fraction of PFK activity in tumors is associated to actin filaments (f-actin). Thus, we investigated whether CTZ would affect the association between PFK and f-actin and we found that the drug directly induces the dissociation of the two proteins in the same extent that it inhibits lactate production, total PFK activity and the particulate PFK activity. We concluded that CTZ disrupts glycolysis on human breast tumor tissues, inhibiting PFK activity by dissociating the enzyme from f-actin.
用人乳腺癌组织以及来自同一患者的正常组织进行处理,用克霉唑(CTZ)处理,并评估其葡萄糖消耗和乳酸生成能力。该处理强烈降低了肿瘤组织的乳酸生成率(85%的抑制作用),而不影响其他测量值,即对照组织的乳酸生成或对照和肿瘤组织的葡萄糖消耗。这一结果与 CTZ 对主要调节糖酵解酶 6-磷酸果糖-1-激酶(PFK)活性的抑制作用直接相关,在肿瘤组织中观察到(84%的抑制作用),而在对照组织中则没有。组织的分级分离表明,这种抑制作用不会发生在酶的可溶性部分,而是仅存在于颗粒部分。先前已经表明,肿瘤中 PFK 活性的颗粒部分与肌动蛋白丝(f-actin)相关。因此,我们研究了 CTZ 是否会影响 PFK 和 f-actin 之间的结合,我们发现该药物直接诱导两种蛋白质以相同的程度解离,从而抑制乳酸生成、总 PFK 活性和颗粒 PFK 活性。我们得出结论,CTZ 通过将酶从 f-actin 上解离来破坏人乳腺癌组织中的糖酵解,从而抑制 PFK 活性。